Efficacy through week52 was assessed by ≥20%/50%/70% improvement in ACR criteria (ACR20/50/70), Health Assessment Questionnaire-Disability Index (HAQ-DI), and ≥75% improvement in Psoriasis Area and Severity Index (PASI75); radiographic progression was measured using the PsA-modified van der Heijde-Sharp (vdH-S) score.
Exploratory endpoints at week 104 included 20, 50 and 70% improvement in ACR criteria (ACR20, 50, 70); 75 and 90% improvement in the Psoriasis Area Severity Index, 28-joint DAS with CRP, presence of dactylitis and enthesitis and other patient-reported outcomes.
Preferences for outcome (probability of 50 % and 90 % improvement, time until response, sustainability of success, probability of mild and severe adverse events, probability of ACR 20 response) and process attributes (treatment location, frequency, duration, and delivery method) were analyzed in 200 participants with moderate-to-severe psoriasis using conjoint analysis.